

Status: Currently Official on 17-Feb-2025
 Official Date: Official Prior to 2013
 Document Type: USP Monographs
 DocId: GUID-34575B6B-21EF-4A1F-9D18-E7AE242CDB5_1_en-US
 DOI: https://doi.org/10.31003/USPNF_M30185_01_01
 DOI Ref: 163uw

© 2025 USPC
 Do not distribute

Erythromycin Delayed-Release Capsules

» Erythromycin Delayed-Release Capsules contain not less than 90.0 percent and not more than 115.0 percent of the labeled amount of erythromycin ($C_{37}H_{67}NO_{13}$).

Packaging and storage—Preserve in tight containers.

USP REFERENCE STANDARDS (11)—

[USP Erythromycin RS](#)

Identification—Prepare a test solution by mixing a quantity of finely ground Capsule contents with methanol to obtain a concentration of about 2.5 mg of erythromycin per mL. Prepare a Standard solution of [USP Erythromycin RS](#) in methanol containing 2.5 mg per mL. Apply separately 10 μ L of each solution to a thin-layer chromatographic plate (see [Chromatography \(621\)](#)) coated with a 0.25-mm layer of chromatographic silica gel. Place the plate in an unlined chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol and chloroform (85:15) until the solvent front has moved about 7 cm. Remove the plate from the chamber, mark the solvent front, and allow the solvent to evaporate. Spray the plate with a mixture of alcohol, *p*-methoxybenzaldehyde, and sulfuric acid (90:5:5). Heat the plate at 100° for 10 minutes, and examine the chromatogram, in which erythromycin appears as a black-to-purple spot: the R_F value of the principal spot obtained from the test solution corresponds to that obtained from the Standard solution.

DISSOLUTION (711)—Proceed as directed for *Procedure for Method B under Apparatus 1 and Apparatus 2, Delayed-Release Dosage Forms*.

Apparatus 1: 50 rpm.

Times: 60 minutes for Acid Stage; 60 minutes for Buffer Stage.

Procedure—Transfer the contents of 1 Capsule to the apparatus. Proceed as directed for Acid Stage, 900 mL of 0.06 N hydrochloric acid being placed in the vessel instead of 1000 mL of 0.1 N hydrochloric acid, and the apparatus operated for 60 minutes instead of 2 hours. Do not perform an analysis at the end of the Acid stage. Continue as directed for Buffer Stage, 900 mL of the pH 6.8 phosphate buffer being used instead of 1000 mL. Determine the amount of $C_{37}H_{67}NO_{13}$ dissolved after 120 minutes by assaying a filtered portion of the solution under test as directed under [Antibiotics—Microbial Assays \(81\)](#).

Tolerances—Not less than 80% (Q) of the labeled amount of $C_{37}H_{67}NO_{13}$ is dissolved in 120 minutes.

WATER DETERMINATION, Method I (921): not more than 7.5%, 20 mL of methanol containing 10% of imidazole being used in place of methanol in the titration vessel.

Assay—Proceed as directed under [Antibiotics—Microbial Assays \(81\)](#), using not less than 5 Capsules blended for about 3 minutes in a high-speed glass blender jar containing 200 mL of methanol. Add 300 mL of Buffer B.3, and blend again for about 3 minutes. Dilute an accurately measured volume of this stock solution quantitatively with Buffer B.3 to obtain a *Test Dilution* having a concentration assumed to be equal to the median dose level of the Standard.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ERYTHROMYCIN DELAYED-RELEASE CAPSULES	Julie Zhang Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	BIO42020 Biologics Monographs 4 - Antibiotics

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 31(1)

Current DocID: GUID-34575B6B-21EF-4A1F-9D18-E7AE242CDB5_1_en-US

DOI: https://doi.org/10.31003/USPNF_M30185_01_01

DOI ref: 163uw